Tuhura Biosciences, Inc./Nv (HURA) Stock Price & Analysis
Tuhura Biosciences, Inc./Nv (HURA) fell 1.86% to USD 2.11 as of July 26, 2026 at 06:45 UTC, according to Nexqual real-time market data.
HURA last closed at USD 2.15; the session ranged USD 2.1–2.21 on volume of 200,889 shares. Market capitalization is $134.37M, with a 52-week range of USD 0.41–3.9 (NCM). Source: Nexqual, July 26, 2026 at 06:45 UTC.
Key Statistics (as of July 26, 2026 at 06:45 UTC)
| Price | USD 2.11 |
|---|---|
| Change | ▼ 1.86% (down) |
| Previous Close | USD 2.15 |
| Open | USD 2.17 |
| Day Range | USD 2.1 – 2.21 |
| 52-Week Range | USD 0.41 – 3.9 |
| Volume | 200,889 shares |
| Market Cap | $134.37M |
| Exchange | NCM |
Technical Analysis (HURA)
Nexqual's technical model rates HURA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 06:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.1 (neutral) |
| vs SMA50 | Below (USD 2.32) |
| MACD | -0.04 (negative) |
Analyst Ratings (HURA)
Wall Street analysts rate HURA "None" based on 5 analysts, with a mean price target of USD 8.04 (range USD 6.2–10), per Nexqual as of July 26, 2026 at 06:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 8.04 |
| High Target | USD 10 |
| Low Target | USD 6.2 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (HURA)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.11 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.21 vs est -0.14 ▼ miss |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
Financials & Fundamentals (HURA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -187.16% |
| Debt / Equity | 1.97 |
| Current Ratio | 1.15 |
| Total Cash | $6.30M |
| Total Debt | $456,926 |
| Free Cash Flow | $-1.62M |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
Financial Health Score (HURA)
Nexqual rates Tuhura Biosciences, Inc./Nv's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 06:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$27M |
| Efficiency | Critical — ROE -187%, ROA -81.9% |
Ownership (HURA)
| Insider Ownership | +34.65% |
|---|---|
| Institutional Ownership | +14.88% |
| Shares Outstanding | 63.68M |
| Float | 39.66M |
| Short % of Float | +13.50% |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
Leadership (HURA)
Tuhura Biosciences, Inc./Nv is led by James A. Bianco (age 68), President, CEO & Director, per Nexqual as of July 26, 2026 at 06:45 UTC.
| President, CEO & Director | James A. Bianco (age 68) |
|---|---|
| Senior Vice President of Clinical Operations | Amanda Garofalo |
Major Backers & Investors (HURA)
Notable institutional backers of Tuhura Biosciences, Inc./Nv include Fidelity, AQR Capital Management, LLC, Apollon Wealth Management, LLC, according to Nexqual as of July 26, 2026 at 06:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.11% |
| AQR Capital Management, LLC | 0.95% |
| Apollon Wealth Management, LLC | 0.25% |
| Charles Schwab | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.57% |
| BlackRock | 6.2% |
| Geode Capital | 1.55% |
| State Street | 0.81% |
| Northern Trust | 0.47% |
| BNY Mellon | 0.33% |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
From Tuhura Biosciences, Inc./Nv's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria.
- We believe we are the first company developing immune modulating ADCs targeting the Delta Opioid Receptor on MDSCs.
- To our knowledge we are the only company developing ADCs targeting MDSCs where our ADCs are designed to be bi-specific/ bi-functional, i.e. , affecting two targets and having two functions: inhibiting tumor associated MDSC-related immune suppression and thereby making tumor susceptible to attack, while localizing checkpoint inhibitors where the tumor resides.
- IFx Innate Immune Agonist Development Program We have developed Immune Fx TM , or IFx, as an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria and to thereby harness the natural power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.
Partnerships
- He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TCMD | Tactile Systems Technology, Inc | USD 27.48 | ▼ 0.51% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.48 | ▼ 4.52% |
| DTCX | Datacentrex, Inc. | USD 1.87 | ▼ 1.58% |
| QNCX | Quince Therapeutics, Inc. | USD 17.86 | ▼ 3.69% |
| KAPA | Kairos Pharma, Ltd. | USD 0.29 | ▼ 8.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 06:45 UTC. This page is informational and not investment advice.